Read our latest updates & insights

Telix Pharmaceuticals announced that the FDA has designated Telix’s monoclonal antibody TLX66 (90Y-besilesomab) an orphan drug for use in conditioning treatment of bone marrow prior to hematopoietic stem cell transplant.

Formycon and Athos KG announced that they have agreed to enter into a long-term strategic partnership regarding biosimilars.  As part of this agreement, Formycon will acquire 100% of the rights in FYB202 (biosimilar ustekinumab candidate) and a 50% stake in FYB201 (biosimil...

Lannett announced that it has commenced dosing in its pivotal trial of biosimilar insulin glargine.

Medical Xpress reports on an Institute of Cancer Research, London, study showing that levels of the protein PD-L1 detected in head and neck tumours can be used to personalise medicine.  Depending on PD-L1 levels, patients should receive personalised medicine of either chemo...

Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded generic formulations and other health care products) for Rs 171 crore on a debt free basis.  The acquisition will support Aurobindo’s plans to manufacture biosimilars and ...

The Office of the Assistant Secretary for Preparedness and Response has announced that it will pause the distribution of sotrovimab in certain US states in which the BA.2 variant has become the dominant COVID-19 strain.  This announcement follows FDA advice which indicates ...

Australia’s TGA approved Celltrion’s Yuflyma® (biosimilar to AbbVie’s Humira® (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis. Crohn’s disease, ulcer...